A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

April 16, 2019

Primary Completion Date

December 13, 2022

Study Completion Date

April 21, 2023

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Durvalumab

Participants will receive 1500 mg Durvalumab monotherapy via IV infusion q4w for up to a maximum of 24 months with the last administration at Week 104.

Trial Locations (28)

19002

Research Site, Guadalajara

20133

Research Site, Milan

20900

Research Site, Monza

22927

Research Site, Großhansdorf

28041

Research Site, Madrid

30459

Research Site, Hanover

30501

Research Site, Gainesville

31400

Research Site, Toulouse

37920

Research Site, Knoxville

41013

Research Site, Seville

42270

Research Site, Saint-Priest-en-Jarez

43126

Research Site, Parma

46015

Research Site, Valencia

47014

Research Site, Meldola

59063

Research Site, Hamm

69126

Research Site, Heidelberg

75248

Research Site, Paris

82131

Research Site, Gauting

83100

Research Site, Avellino

94010

Research Site, Créteil

00152

Research Site, Roma

08907

Research Site, Barcelona

LS9 7TF

Research Site, Leeds

M20 4BX

Research Site, Manchester

TS4 3BW

Research Site, Middlesbrough

NG5 1PB

Research Site, Nottingham

S10 2SJ

Research Site, Sheffield

ST4 6QG

Research Site, Stoke-on-Trent

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY